In a recent episode of the stock market drama, shares of tech juggernaut Cellebrite DI Ltd (CLBT) have soared past the average analyst 12-month target price of $10.00, reaching a striking $10.74 per share. When a stock triumphs over a target price, analysts face a crossroads: downgrade on valuation or ratchet up their target price to more stratospheric levels. Their decision may hinge on the fundamental business landscape that is propelling the stock skyward. Should the company’s prospects be boiling, it’s only natural to foster a target price surge.
The Zacks coverage universe features 6 distinct analyst targets contributing to the overall average for Cellebrite DI Ltd. Yet, as is often the case with averages, it’s exactly that – a mere mathematical mean. A range of expectations exists, with some analysts eyeing a conservative $9.00 and others dangling an ambitious $11.00. The standard deviation rings in at $0.632.
Scanning the average CLBT price target initially taps into the “wisdom of crowds” ethos, pooling the insights of all individual contributors to generate the ultimate figure. With CLBT breaching the average target price of $10.00 per share, investors have received a powerful signal to reevaluate the company and ponder: is $10.00 just a pit stop on the way to loftier heights, or has the valuation stretched to a point where it warrants pocketing some chips? Let’s delve into the current musings of analysts covering Cellebrite DI Ltd:
| Recent CLBT Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Month Ago | 3 Month Ago |
| Strong buy ratings: | 4 | 4 | 4 | 4 |
| Buy ratings: | 1 | 1 | 1 | 1 |
| Hold ratings: | 2 | 2 | 2 | 2 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.71 | 1.71 | 1.71 | 1.71 |
The average rating at the bottom of the table sits on a scale from 1 to 5, where 1 denotes a Strong Buy and 5 indicates a Strong Sell. Data for this article was provided by Zacks Investment Research via Quandl.com. Get your hands on the latest Zacks research report on CLBT — it’s on the house.
Discover 10 ETFs With Strong Upside to Analyst Targets »
Also see:
• Cheap Technology Shares
• Funds Holding RNDM
• Funds Holding SYBX
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
